JP2010514686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514686A5 JP2010514686A5 JP2009543183A JP2009543183A JP2010514686A5 JP 2010514686 A5 JP2010514686 A5 JP 2010514686A5 JP 2009543183 A JP2009543183 A JP 2009543183A JP 2009543183 A JP2009543183 A JP 2009543183A JP 2010514686 A5 JP2010514686 A5 JP 2010514686A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- aryl
- alkoxy
- alkanoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, substituted amino Chemical group 0.000 claims 54
- 125000003282 alkyl amino group Chemical group 0.000 claims 28
- 125000004103 aminoalkyl group Chemical group 0.000 claims 28
- 125000001589 carboacyl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 20
- 125000000592 heterocycloalkyl group Chemical class 0.000 claims 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 125000000547 substituted alkyl group Chemical group 0.000 claims 19
- 150000001408 amides Chemical class 0.000 claims 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 17
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 14
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 10
- 125000004423 acyloxy group Chemical group 0.000 claims 10
- 125000005236 alkanoylamino group Chemical group 0.000 claims 10
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 10
- 125000005239 aroylamino group Chemical group 0.000 claims 10
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 10
- 125000001769 aryl amino group Chemical group 0.000 claims 10
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 10
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 10
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 10
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 9
- 125000004414 alkyl thio group Chemical group 0.000 claims 9
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004001 thioalkyl group Chemical group 0.000 claims 9
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 7
- 125000001118 alkylidene group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 6
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 125000005110 aryl thio group Chemical group 0.000 claims 6
- 125000001951 carbamoylamino group Chemical class C(N)(=O)N* 0.000 claims 6
- 229940124530 sulfonamide Drugs 0.000 claims 6
- 150000003456 sulfonamides Chemical class 0.000 claims 6
- XIKRJRRZTIMYRY-UHFFFAOYSA-N (cyanosulfonylamino)urea Chemical class NC(=O)NNS(=O)(=O)C#N XIKRJRRZTIMYRY-UHFFFAOYSA-N 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000001336 alkenes Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229940127084 other anti-cancer agent Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87087206P | 2006-12-20 | 2006-12-20 | |
| US60/870,872 | 2006-12-20 | ||
| PCT/US2007/088124 WO2008079873A2 (en) | 2006-12-20 | 2007-12-19 | Thiazolyl compounds useful as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514686A JP2010514686A (ja) | 2010-05-06 |
| JP2010514686A5 true JP2010514686A5 (enExample) | 2011-07-28 |
| JP5225288B2 JP5225288B2 (ja) | 2013-07-03 |
Family
ID=39563189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543183A Expired - Fee Related JP5225288B2 (ja) | 2006-12-20 | 2007-12-19 | キナーゼ阻害剤として有用なチアゾリル化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8148400B2 (enExample) |
| EP (1) | EP2099794B1 (enExample) |
| JP (1) | JP5225288B2 (enExample) |
| CN (1) | CN101652363B (enExample) |
| NO (1) | NO20092035L (enExample) |
| WO (1) | WO2008079873A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5385895B2 (ja) * | 2007-04-10 | 2014-01-08 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なチアゾリル化合物 |
| EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
| EP3805218A1 (en) * | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| JP7028766B2 (ja) * | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| CN106932502B (zh) * | 2015-12-31 | 2021-05-18 | 上海奥博生物医药股份有限公司 | 一种索拉菲尼中4-氯-2-吡啶甲酸甲酯含量的测定方法 |
| CN107043375B (zh) * | 2017-04-28 | 2020-03-20 | 江苏食品药品职业技术学院 | 一种制备达沙替尼及其中间体的新方法 |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| KR102253652B1 (ko) * | 2019-08-19 | 2021-05-18 | 주식회사 셀젠텍 | 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 약학적 조성물 |
| WO2023134764A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3113902A (en) * | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| WO2004071440A2 (en) * | 2003-02-06 | 2004-08-26 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
| JP5385895B2 (ja) * | 2007-04-10 | 2014-01-08 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なチアゾリル化合物 |
-
2007
- 2007-12-19 US US12/519,597 patent/US8148400B2/en active Active
- 2007-12-19 EP EP07869520.2A patent/EP2099794B1/en active Active
- 2007-12-19 CN CN2007800515523A patent/CN101652363B/zh not_active Expired - Fee Related
- 2007-12-19 JP JP2009543183A patent/JP5225288B2/ja not_active Expired - Fee Related
- 2007-12-19 WO PCT/US2007/088124 patent/WO2008079873A2/en not_active Ceased
-
2009
- 2009-05-26 NO NO20092035A patent/NO20092035L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524957A5 (enExample) | ||
| EP4605399A1 (en) | Oxazepine compounds comprising a 6-aza moiety and uses thereof | |
| ES2821790T3 (es) | Moduladores de la vía de estrés integrada | |
| CN105916845B (zh) | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 | |
| CN105899491B (zh) | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 | |
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| CN107108637B (zh) | 三唑并嘧啶化合物及其用途 | |
| JP2014503567A5 (enExample) | ||
| KR20180017013A (ko) | K-Ras 조절제 | |
| CN114057689A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| CN107787323A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| HRP20110566T1 (hr) | Azaindoli kao inhibitori jak i drugih kinaza | |
| WO2017146236A1 (ja) | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 | |
| CN105899493A (zh) | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 | |
| JP2014502601A (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| EP3423112A1 (en) | Hsp90 inhibitor drug conjugates | |
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| JP2021107456A (ja) | インドリノン化合物の使用 | |
| CA3139969A1 (en) | Small molecule inhibitors of src tyrosine kinase | |
| JP2025509965A (ja) | がんを治療するための組成物及び方法 | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| TWI796326B (zh) | 含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途 | |
| AU2019216757A1 (en) | Mebendazole prodrugs with enhanced solubility and oral bioavailability | |
| JP2017509672A5 (enExample) | ||
| AU2019379310B2 (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer |